Evolution of the Randomized Controlled Trial in Oncology Over Three Decades

Christopher M. Booth(Queen's University), Monika K. Krzyzanowska(American Society of Clinical Oncology), Lisa Wang(University of Toronto), David W. Cescon(Princess Margaret Cancer Centre), Ian F. Tannock(Princess Margaret Cancer Centre)
Journal of Clinical Oncology
October 28, 2008
10.1200/jco.2008.16.5456
Cited by 158

Related Papers

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k
Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
|JAMA|2003|1.4k
Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer
|JAMA|2011|632